When Turing Pharmaceuticals CEO Martin Shkreli got hit with a ton of deserved backlash over his decision to hike the price of Daraprim over 5,000%, he decided to change his mind and lower it again.

That was September 22, however, and the drug--which can provide crucial treatment for those living with HIV--has still not come down in price.

Maybe he thought we forgot?

But bad news for Shkreli, we didn't. And neither did the Human Rights Campaign.

“It has been more than two weeks since Mr. Shkreli publicly pledged to roll back his company’s unconscionable price hike on this lifesaving treatment for those with compromised immune systems -- including many pregnant women and people living with HIV,” said HRC President Chad Griffin.

“Increasing the per-pill price of Daraprim from $13.50 to $750 represents the worst in predatory pricing," he continued, "and we will continue to demand that Mr. Shkreli make good on his promise, and that officials address this exploitative price gouging.”

Griffin has written to the New York Attorney General and other officials, urging them to investigate Turing’s reckless behavior.

Meanwhile, HRC is asking its members to use the hashtag #rollitback to keep the pressure on Turing Pharmaceuticals and Shkreli and get them to restore the original price.

h/t: HRC